Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug

Sabha, Marwa; Siaton, Bernadette; Hochberg, Marc C.

doi:10.1080/13543784.2020.1842357

Cited by 21 publications

(25 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lorecivivint (SM04690, Figure 3) is a small-molecule Wnt pathway modulator currently in development as a potential DMOAD for the treatment of knee OA [81]. It modulates the Wnt signaling pathway by inhibiting CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1 A which are molecular regulators in Wnt signaling, chondrogenesis, and inflammation [82].…”

Section: Disease Modifying Drugs For Osteoarthritis (Dmoads)mentioning

confidence: 99%

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment

Nowaczyk

Szwedowski

Dallo³

et al. 2022

IJMS

View full text Add to dashboard Cite

Osteoarthritis (OA) can be defined as the result of pathological processes of various etiologies leading to damage to the articular structures. Although the mechanism of degenerative changes has become better understood due to the plethora of biochemical and genetic studies, the drug that could stop the degenerative cascade is still unknown. All available forms of OA therapy are based on symptomatic treatment. According to actual guidelines, comprehensive treatment of OA should always include a combination of various therapeutic options aimed at common goals, which are pain relief in the first place, and then the improvement of function. Local treatment has become more common practice, which takes place between rehabilitation and pharmacological treatment in the hierarchy of procedures. Only in the case of no improvement and the presence of advanced lesions visible in imaging tests, should surgery be considered. Currently, an increasing number of studies are being published suggesting that intra-articular injections may be as effective or even more effective than non-steroidal anti-inflammatory drugs (NSAIDs) and result in fewer systemic adverse events. The most commonly used preparations are hyaluronic acid (HA), glucocorticosteroids (GS), and also platelet-rich plasma (PRP) in recent years. This review aims to present the mechanism of action and clinical effectiveness of different pharmacological options in relieving pain and improving functions in OA as well as the emerging approach in intra-articular treatment with PRP.

show abstract

Section: Disease Modifying Drugs For Osteoarthritis (Dmoads)mentioning

confidence: 99%

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment

Nowaczyk

Szwedowski

Dallo³

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The first promising results of a phase II randomized trial were published in 2020 [ 129 ]. Even though this trial did not meet its primary endpoint, preplanned analyses did identify a target population for further evaluation of its potential as a DMOAD, and phase 3 trials are ongoing [ 130 ].…”

Section: The Role Of Proteases and Cytokines In Oamentioning

confidence: 99%

Osteoarthritis: Novel Molecular Mechanisms Increase Our Understanding of the Disease Pathology

Grässel

Zaucke

Madry

2021

JCM

View full text Add to dashboard Cite

Although osteoarthritis (OA) is the most common musculoskeletal condition that causes significant health and social problems worldwide, its exact etiology is still unclear. With an aging and increasingly obese population, OA is becoming even more prevalent than in previous decades. Up to 35% of the world’s population over 60 years of age suffers from symptomatic (painful, disabling) OA. The disease poses a tremendous economic burden on the health-care system and society for diagnosis, treatment, sick leave, rehabilitation, and early retirement. Most patients also experience sleep disturbances, reduced capability for exercising, lifting, and walking and are less capable of working, and maintaining an independent lifestyle. For patients, the major problem is disability, resulting from joint tissue destruction and pain. So far, there is no therapy available that effectively arrests structural deterioration of cartilage and bone or is able to successfully reverse any of the existing structural defects. Here, we elucidate novel concepts and hypotheses regarding disease progression and pathology, which are relevant for understanding underlying the molecular mechanisms as a prerequisite for future therapeutic approaches. Emphasis is placed on topographical modeling of the disease, the role of proteases and cytokines in OA, and the impact of the peripheral nervous system and its neuropeptides.

show abstract

“…No results are currently available for multiple rounds of administration of the drug. However, if the ongoing phase III trials exhibit good clinical efficacy profiles and marginal side effects [ 152 ], lorecivivint will become a promising DMOAD approved for knee OA therapy compared with intra-articular corticosteroid and hyaluronate injections [ 153 ]. Lietman et al also reported that inhibiting Wnt/β-catenin signaling could ameliorate OA [ 154 ].…”

Section: Small Molecules For Manipulating Chondrocyte Pathological Phenotypementioning

confidence: 99%

Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs

Chen

Yao

et al. 2021

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug

Cited by 21 publications

References 36 publications

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment

Osteoarthritis: Novel Molecular Mechanisms Increase Our Understanding of the Disease Pathology

Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs

Contact Info

Product

Resources

About